Asuragen, Inc.
134 articles about Asuragen, Inc.
-
Asuragen Announces Launch of AmplideX® PCR/CE HTT Kit
1/9/2019
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced the launch of the AmplideX® PCR/CE HTT Kit*.
-
Asuragen Launches Assay to Aid in the Diagnosis of Myotonic Dystrophy Type I (DM1)
12/4/2018
The AmplideX® DM1 Dx Kit is now available in countries accepting the CE mark
-
Asuragen Announces Health Canada Approval of the QuantideX® qPCR BCR-ABL IS Kit
11/13/2018
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced that its QuantideX qPCR BCR-ABL IS Kit has received Health Canada approval
-
Asuragen to Present at 2018 Association for Molecular Pathology (AMP) Annual Meeting
10/23/2018
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, will host a corporate workshop,
-
New Laboratory Screening Test for Fragile X Syndrome Shortly after Birth Now Ready for Pivotal North Carolina Early Check Clinical Study
10/22/2018
Scientific collaboration between RTI International and Asuragen leads to test validation
-
Asuragen Announces New Commercial Leadership Appointment
10/16/2018
Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced that it has hired Tom Copa as senior vice president, commercial operations.
-
Asuragen to Present at 2018 American Society of Human Genetics Annual Meeting
10/9/2018
Scientific posters and workshop presentation will highlight the AmplideX® product portfolio.
-
Asuragen to Host Panel at Upcoming World Clinical Biomarkers & Companion Diagnostic Summit
9/25/2018
Roundtable will address strategies for CDx development beyond oncology
-
Asuragen Expands Oncology Portfolio with CE Marking and Launch of QuantideX® NGS DNA Hotspot 21 Kit
9/5/2018
The panel accurately and sensitively detects over 1600 variants of clinical significance
-
Asuragen Expands AmplideX® Technology and Product Line with Launch of PCR/CE SMN1 Kit
7/26/2018
The AmplideX PCR/CE SMN1 kit allows laboratories to quickly and easily determine SMN1 exon 7 copy number
-
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
-
Asuragen Obtains CE Mark of QuantideX qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer
1/17/2018
Asuragen announced that it has expanded its CE mark of the QuantideX qPCR BCR-ABL IS Kit and QuantideX qPCR BCR-ABL minor Kit to include clinical use on the Roche Diagnostics cobas z 480 Analyzer.
-
Asuragen to Present at Upcoming 2017 Association for Molecular Pathology (AMP) Annual Meeting
11/8/2017
Asuragen will host a corporate workshop and present three posters at the 2017 Association for Molecular Pathology (AMP) Conference November 15-18 in Salt Lake City.
-
Asuragen, Inc. To Present At 2017 American Society of Human Genetics (ASHG) Conference
10/10/2017
-
Asuragen, Inc. Expands QuantideX qPCR BCR-ABL Portfolio For Monitoring Molecular Response In Chronic Myeloid Leukemia
8/3/2017
-
Asuragen, Inc. Strengthens Repetitive Sequence And Short Structural Variant Intellectual Property Portfolio
4/25/2017
-
Asuragen, Inc. Launches The Amplidex PCR/CE TOMM40 Kit1 Expanding Portfolio Into The Alzheimer’s And Cognitive Impairment Space
3/14/2017
-
Asuragen, Inc. And Thermo Fisher Scientific To Collaborate On Diagnostic Kits For 3500 Dx Series Genetic Analyzer
2/20/2017
-
Asuragen, Inc. Launches QuantideX NGS RNA Lung Cancer Kit (RUO)
11/1/2016
-
Asuragen, Inc. Develops Armored RNA Quant Zika Virus Control
8/9/2016